Projet LysoMod (Horizon 2020, appel à projets 2016)
Action : Staff Exchanges
Panel : Life Sciences
Statut du projet : CLOSED

LysoMod will innovate in the area of personalized medicine for disorders linked to lysosomal dysfunction. This will be achieved by implementing a collaborative staff-exchange program between highly complementary and multidisciplinary academic and non-academic partners with expertise in pharmacology, medicinal chemistry, cell biology, biochemistry, mouse and human genetics, transcriptomics, proteomics and lipidomics. Based on the critical role that lysosomes play in cells, a better understanding of lysosomal function will have a major impact on human health, fostering the development of new strategies to improve quality of life for people affected by a variety of diseases, ranging from lysosomal storage diseases (LSDs) to age-related neurodegenerative disorders. LysoMod’s specific objectives are: 1) to develop and further optimize existing therapies for LSDs; 2) to identify new targets for personalized therapies for LSDs; and 3) to investigate the cross-talk between lysosomal function, signalling pathways and gene expression regulation. The pioneer work of a participant in the consortium led to the development of a drug that is approved for clinical use. LysoMod will i) investigate the mechanisms of action of this and other drugs in lysosome-related disorder; ii) identify modifier genes involved in LSD pathology and test their potential as new targets for personalized therapeutic approaches; iii) identify candidate RNAs that can be targeted to enhance lysosomal function. The companies in the consortium will ensure a rapid transfer of new knowledge into applications for diagnostics and clinical trials. Prioritising lysosomal dysfunction as a highly relevant biomedical problem, the LysoMod consortium will implement a mentored staff-exchange program to provide young researchers with high-level training in innovative approaches for exploring biological systems, preparing the next generation of researchers for careers either in the private or public health sectors.

Mots clés : lysosome, lysosomal  storage diseases, lipidomics

Participants :
- University of Buenos Aires (Argentine) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Children's Hospital of Philadelphia (Etats-Unis) — Partner, organization partner, Autres, subvention : 0.0 €
- Intrabio ltd (Royaume-Uni) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 22500.0 €
- Genomed, diagnosticos de medicina molecular sa (Portugal) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 276750.0 €
- Weizmann Institute of Science (Israël) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 22950.0 €
- Lipotype (Allemagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 4500.0 €
- University of Sussex (Royaume-Uni) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 81000.0 €
- Universidad del Desarrollo (Chili) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- University of Oxford (Royaume-Uni) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 207000.0 €
- University of Lisbon (Portugal) — Coordinator, beneficiary, Recherche, subvention : 343800.0 €
- Telethon Foundation (Italie) — Partner, beneficiary, Recherche, subvention : 0.0 €
- Institute of Biochemistry (Roumanie) — Partner, beneficiary, Recherche, subvention : 99000.0 €
- Chronos biosystems srl (Roumanie) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 45000.0 €
- Pontificia Universidad Católica de Chile (Chili) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €